Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Jun 30, 2017
Filed with the SEC on Jul 28, 2017 and accepted by EDGAR at Jul 28, 2017, 20:23 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 6 months2017-01-01 to 2017-06-30 | $116.8m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2017-04-01 to 2017-06-30 | $289.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2017-01-01 to 2017-06-30 | $563.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-04-01 to 2017-06-30 | $127.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2017-01-01 to 2017-06-30 | $240.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-04-01 to 2017-06-30 | $52.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-01-01 to 2017-06-30 | $323.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-04-01 to 2017-06-30 | $4.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-01-01 to 2017-06-30 | $8.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-04-01 to 2017-06-30 | $18.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-01-01 to 2017-06-30 | $265.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-04-01 to 2017-06-30 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2017-01-01 to 2017-06-30 | $1.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-04-01 to 2017-06-30 | $0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2017-01-01 to 2017-06-30 | $1.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-04-01 to 2017-06-30 | 251,635,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2017-01-01 to 2017-06-30 | 250,199,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2017-01-01 to 2017-06-30 | $447.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2017-01-01 to 2017-06-30 | $28.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-06-30 | $1.22bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-06-30 | $2.18bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-06-30 | $3.29bn | us-gaap:Assets |
| Current liabilities | At period end2017-06-30 | $625.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-06-30 | $1.42bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-06-30 | $1.67bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-17-000047. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.